Schizophrenia Research
Volume 91, Issue 1 , Pages 107-111 , March 2007

Stability of attention deficits in schizophrenia

  • Josette G. Harris

      Affiliations

    • University of Colorado School of Medicine, Department of Psychiatry, C268-71, 4200 E. 9th Avenue, Denver, CO 80262, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 303 315 4610; fax: +1 303 315 5347.
    • ,
  • Arpi Minassian

      Affiliations

    • University of California San Diego, Department of Psychiatry, United States
    • ,
  • Willliam Perry

      Affiliations

    • University of California San Diego, Department of Psychiatry, United States

Received 19 July 2006 ,Revised 8 December 2006 ,Accepted 14 December 2006.

References 

  1. Benton AL, Hamsher K des, Varney NR, Spreen O. Contributions to Neuropsychological Assessment. New York: Oxford University Press; 1983;
  2. Brickenkamp R, Zillmer E. d2 Test of Attention. 1st U.S. ed.. Gottingen: Hogrefe & Huber; 1998;
  3. Elevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000;14:1–21
  4. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1997;
  5. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper T, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75–85
  6. Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry. 1996;57(suppl 9):62–65
  7. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 1993;162:43–48
  8. Goldstein G. Cognitive heterogeneity in psychopathology: the case of schizophrenia. In:  Vernon PA editors. The Neuropsychology of Individual Differences. San Diego, CA: Academic Press; 1994;p. 209–233
  9. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  10. Gur R, Kohler C, Ragland JD, Siegel SJ, Bilker WB, Loughead J, et al. Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. Neuropsychopharmacology. 2003;28(11):2029–2036
  11. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 1993;34:702–712
  12. Harris JG, Adler LE, Young DA, Cullum CM, Rilling LM, Cicerello A, et al. Neuropsychological dysfunction in parents of schizophrenics. Schizophr. Res. 1996;20:253–260
  13. Harris JG, Kongs S, Allensworth DA, Sullivan B, Zerbe G, Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:1378–1385
  14. Harvey PD. Ziprasidone and cognition: the evolving story. J. Clin. Psychiatry. 2003;64(suppl 19):33–39
  15. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry. 2001;58(1):24–32
  16. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 1994;49:271–277
  17. Levin ED, Wilson W, Rose J, McEvoy J. Nicotine–haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429–436
  18. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed.. New York: Oxford University Press; 2004;
  19. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry. 2000;157:767–771
  20. Liu SK, Chen WJ, Chang C-J, Lin H-N. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia. Neuropsychopharmacology. 2000;22:311–319
  21. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999;25:233–255
  22. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28(8):1491–1500
  23. Yee CM, Nuechterlein KH, Morris SE, White PM. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J. Abnorm. Psychology. 1998;107(4):691–698

PII: S0920-9964(07)00027-8

doi: 10.1016/j.schres.2006.12.021

Schizophrenia Research
Volume 91, Issue 1 , Pages 107-111 , March 2007

Article Tools